CABA

Cabaletta Bio, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-23

Figures on this page computed 2026-11-08 12:40 UTC

Last close

1.30USD

Market data, 2026-11-06

Except where said otherwise: 10-K for 2025, filed 2026-03-23

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001759138-26-000011
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-23
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001759138-26-000011
Reported in
USD
- 10-K for 2025, filed 2026-03-23
- 10-K for 2025, filed 2026-03-23
- 10-K for 2025, filed 2026-03-23
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-23
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001759138-26-000011
Reported in
USD
- 10-K for 2025, filed 2026-03-23
- 10-K for 2025, filed 2026-03-23
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001759138-26-000011
Reported in
USD
- 10-K for 2025, filed 2026-03-23
- 10-K for 2025, filed 2026-03-23
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001759138-26-000011
Reported in
USD
- 10-K for 2025, filed 2026-03-23
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.26 against 0.46 on the market's range.

Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

n/a

2.94x

2.29x

n/a

0.17x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-06

Each against its own average

3 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-23

Salesn/a
Its own average over 0 years.
Profit2.94x
Its own average over 9 years, -57.0M.
Free cash flow2.29x
Its own average over 7 years, -57.9M.
Debtn/a
Its own average over 0 years.
Price0.17x
Its own average over 8 years, 8. Market data, 2026-11-06

Profit is furthest from its own average, at 2.94 times.

Profit is 2.94 times its own 9-year average; Free cash flow is 2.29 times its own 7-year average; Price is 0.17 times its own 8-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-23

Sales against its own 0-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001759138-26-000011
Reported in
USD
The filing itself
Profit against its own 9-year average2.94
Source
filed
Statement
income
Fiscal year
2025
Accession
0001759138-26-000011
Reported in
USD
The filing itself
Free cash flow against its own 7-year average2.29
Source
filed
Statement
income
Fiscal year
2025
Accession
0001759138-26-000011
Reported in
USD
The filing itself
Debt against its own 0-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001759138-26-000011
Reported in
USD
The filing itself
Price against its own 8-year average0.17Market data, 2026-11-06
Source
market
Taken on
2026-11-06
Reported in
USD